Quick Answer
Atara Biotherapeutics, Inc. reported Stockholders Equity of -$38.50 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed an increase of +60.4% in Stockholders Equity from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: -$23.03 million | Q1 2015: $166.09 million | Q2 2015: $149.26 million | Q3 2015: $333.75 million | Q1 2016: $303.83 million | Q2 2016: $290.25 million | Q3 2016: $270.20 million | Q1 2017: $233.13 million | Q2 2017: $221.14 million | Q3 2017: $205.96 million | Q1 2018: $439.18 million | Q2 2018: $452.50 million | Q3 2018: $403.05 million | Q1 2019: $283.93 million | Q2 2019: $232.28 million | Q3 2019: $318.44 million | Q1 2020: $252.82 million | Q2 2020: $381.13 million | Q3 2020: $353.94 million | Q1 2021: $399.04 million | Q2 2021: $331.54 million | Q3 2021: $310.14 million | Q1 2022: $224.32 million | Q2 2022: $257.48 million | Q3 2022: $187.11 million | Q1 2023: $64.96 million | Q2 2023: $7.45 million | Q3 2023: -$50.84 million | Q1 2024: -$98.31 million | Q2 2024: -$110.87 million | Q3 2024: -$90.54 million | Q1 2025: -$55.07 million | Q2 2025: -$35.04 million | Q3 2025: -$36.63 million.
- Over the full 14 years of available data (2012 to 2025), Atara Biotherapeutics, Inc.'s Stockholders Equity has declined by 933.1%.
- Historical annual values: Fiscal year 2025: -$38.50 million | Fiscal year 2024: -$97.28 million | Fiscal year 2023: $99.23 million | Fiscal year 2022: $126.64 million | Fiscal year 2021: $279.61 million | Fiscal year 2020: $462.34 million | Fiscal year 2019: $290.78 million | Fiscal year 2018: $339.22 million | Fiscal year 2017: $177.86 million | Fiscal year 2016: $253.74 million | Fiscal year 2015: $315.10 million | Fiscal year 2014: $103.18 million | Fiscal year 2013: -$11.02 million | Fiscal year 2012: -$3.73 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: